Essity AB (ESSITY-B.ST) is a leading global hygiene and health company with a portfolio of strong brands in tissue, personal care, and incontinence products. The company is benefiting from a margin recovery driven by cost savings, price mix improvements, and easing raw material costs. Innovation in sustainable products and digitalization are key growth drivers. With a solid balance sheet and a history of consistent dividend payments, Essity offers a defensive yet growing profile in the consumer staples space.
Investment Thesis
Essity is a consumer compounder with durable competitive advantages in essential categories. The company is executing a margin improvement program targeting €1.5 billion in savings by 2025, which is on track. Revenue growth is supported by premiumization and emerging market expansion. Free cash flow generation is robust, enabling debt reduction and shareholder returns.
12-Month Catalysts
- Margin expansion from cost savings and raw material tailwinds.
- Innovation in sustainable products (e.g., plant-based materials) driving market share gains.
- Potential divestiture of non-core assets to unlock value.
Key Risks
- Raw material cost volatility (pulp, oil-based inputs).
- Intense competition from private labels and larger peers.
Valuation Summary
Essity trades at approximately 15x forward P/E, a discount to its historical average and peers like Kimberly-Clark. With expected EPS growth of 8-10% and a dividend yield of ~3.5%, the risk-reward is attractive.
Balance Sheet Summary
Net debt to EBITDA is around 1.5x, with strong free cash flow conversion. The company has investment-grade credit ratings and ample liquidity.
Disclaimer: This is not financial advice. Investing involves risk. Please conduct your own research.